BT-20

BT-20 is a breast cancer cell line derived from a 74-year-old human female in 1958 by E.Y. Lasfargues and L. Ozzello.^[1] The cells technically came from a triple-negative breast cancer, which was caused by an invasive ductal carcinoma in the mammary gland. BT-20 cells are known to have amplified regions of chromosomes 6, 11, and 20, with most cells being hyperdiploid.^[2] The cells express an estrogen receptor with a deletion of exon 5, and are used in preclinical studies of breast cancer.

References

^ Lasfargues, EY; Ozzello, L (1958). "Cultivation of human breast carcinomas". Journal of the National Cancer Institute. 21 (6): 1131–1147. PMID 13611537.
^ "BT20". pawefish.uk. Retrieved 10 April 2018.

External links

Cellosaurus entry for BT-20

This oncology article is a stub. You can help Wikipedia by expanding it.

[1] Lasfargues, EY; Ozzello, L (1958). "Cultivation of human breast carcinomas". Journal of the National Cancer Institute. 21 (6): 1131–1147. PMID 13611537.

[2] "BT20". pawefish.uk. Retrieved 10 April 2018.

[1]

[2]